Lifecare ASA: Mandatory notification of trade

Reference is made to announcements made by Lifecare ASA (the "Company") on 23 January 2026 and 29 January 2026 regarding the allocation of in total 940,261 shares and 1,410,392 warrants to Hans Hekland, board member of the Company, in a rights issue and as settlement of his entitlement to underwriting commission as an underwriter of the rights issue. The Company has been informed that all such shares and warrants that were allocated to Hans Hekland have been agreed transferred to Hannibal Invest AS, a company closely associated with Hans Hekland. The transfer does not affect the total number of issued shares or warrants in the Company. Please see the attached PDMR form for further details. About us Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets. Contacts For further information, please contact: Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40 Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42 This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-29 17:04 CET.